HR Execs on the Move

Codexis

www.codexis.com

 
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company`s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.codexis.com
  • 200 Penobscot Drive
    Redwood City, CA USA 94063
  • Phone: 650.421.8100

Executives

Name Title Contact Details
Lyndsey Clogston
Director, HR and Talent Management Profile
Svetlana Sowers
Director, OEM Sales Profile
Catherine Mesgar
Senior Director, People Operations and Technology Profile

Similar Companies

Therapure

Therapure is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

HealthSource Solutions

HealthSource Solutions is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayer AG

Bayer AG is a Baytown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crosscart Inc

Crosscart Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CARsgen

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.